Harel Insurance Investments & Financial Services Ltd. Sells 5,232 Shares of Medpace Holdings, Inc. $MEDP

Harel Insurance Investments & Financial Services Ltd. reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,510 shares of the company’s stock after selling 5,232 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Medpace were worth $5,910,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. Quent Capital LLC bought a new stake in Medpace in the third quarter valued at $25,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Employees Retirement System of Texas bought a new stake in shares of Medpace during the 2nd quarter valued at about $36,000. IFP Advisors Inc increased its position in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after buying an additional 134 shares during the period. Finally, Hantz Financial Services Inc. increased its position in shares of Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after buying an additional 203 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.2%

Shares of NASDAQ:MEDP opened at $610.90 on Friday. The stock has a fifty day simple moving average of $582.73 and a two-hundred day simple moving average of $511.35. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The stock has a market capitalization of $17.21 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 387,925 shares of company stock valued at $233,386,647. Insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MEDP shares. TD Cowen lifted their price objective on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Robert W. Baird set a $613.00 target price on Medpace in a research note on Friday, October 24th. BMO Capital Markets started coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target on the stock. Truist Financial set a $555.00 price objective on Medpace in a report on Monday, October 27th. Finally, Mizuho set a $660.00 target price on shares of Medpace in a report on Friday, January 9th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $491.27.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.